Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy

Published:2017-08-01 Issue:2 Volume:166 Page:473-480
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Kang Young-Joon,Han Wonshik,Park Soojin,You Ji Young,Yi Ha Woo,Park Sungmin,Nam Sanggeun,Kim Joo Heung,Yun Keong Won,Kim Hee Jeong,Ahn Sei Hyun,Park Seho,Lee Jeong Eon,Lee Eun Sook,Noh Dong-Young,Lee Jong Won^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4423-1/fulltext.html

Reference25 articles.

1. Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference C (2002) Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 94(10):2542–2551

2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant B, Bowel P (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888. doi: 10.1016/S1470-2045(07)70278-4

3. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230(1):72–78

4. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Neo AST (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640. doi: 10.1016/S0140-6736(11)61847-3

5. King TA, Morrow M (2015) Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol 12(6):335–343. doi: 10.1038/nrclinonc.2015.63

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting axillary lymph node metastasis in breast cancer based on ultrasound radiofrequency time-series analysis;Acta Radiologica;2024-09-02

2. Feasibility and Efficacy of Sentinel Lymph Node Mapping in Gastric Cancer;Annals of Surgical Oncology;2024-08-03

3. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes;Anticancer Research;2024-04-27

4. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer;Cancer Treatment Reviews;2024-02

5. Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta‐Analysis;The Breast Journal;2024-01